Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Platelets
|
December 17, 2010
A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits
Vassiliki D Roussa, Eleni M Stathopoulou, Nikolaos D Papamichael, et al.
Clinical Genetics
|
November 25, 2016
BRCA1 and BRCA2 mutation testing in Cyprus; a population based study
M A Loizidou, A Hadjisavvas, P Pirpa, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping
J Sgouros, A Eliades, K Papadopoulou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 13, 2014
Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
D Papamichael, R A Audisio, B Glimelius, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont, A Figer, M Seymour, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese
|
February 1, 2022
The administration of the synthetic peptide YMESRADR with a low aspirin dose significantly augments its antiplatelet effect, in contrast to the highly constrained peptide (S,S) PSRCDCR-NH<sub>2</sub>. An experimental study
K V Englezopoulos, E M Stathopoulou, V Moussis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2023
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A de Gramont, A Figer, M Seymour, et al.
ESMO Open
|
September 4, 2024
Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working Group
K P Loh, G Liposits, S P Arora, et al.
ESMO Open
|
March 27, 2026
The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer
C Baldini, A R A Mislang, K-L Cheung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 28, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
E S M van Aken, B Devnani, A Prelaj, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Platelets
|
December 17, 2010
A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits
Vassiliki D Roussa, Eleni M Stathopoulou, Nikolaos D Papamichael, et al.
Clinical Genetics
|
November 25, 2016
BRCA1 and BRCA2 mutation testing in Cyprus; a population based study
M A Loizidou, A Hadjisavvas, P Pirpa, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping
J Sgouros, A Eliades, K Papadopoulou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 13, 2014
Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
D Papamichael, R A Audisio, B Glimelius, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont, A Figer, M Seymour, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese
|
February 1, 2022
The administration of the synthetic peptide YMESRADR with a low aspirin dose significantly augments its antiplatelet effect, in contrast to the highly constrained peptide (S,S) PSRCDCR-NH<sub>2</sub>. An experimental study
K V Englezopoulos, E M Stathopoulou, V Moussis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2023
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A de Gramont, A Figer, M Seymour, et al.
ESMO Open
|
September 4, 2024
Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working Group
K P Loh, G Liposits, S P Arora, et al.
ESMO Open
|
March 27, 2026
The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer
C Baldini, A R A Mislang, K-L Cheung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 28, 2025
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors
E S M van Aken, B Devnani, A Prelaj, et al.
Page
of 6